TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02208596
Drug: pentazocine
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every patient enrolled in the study will be given 15 mg pentazocine before induction.
Study: NCT02208596
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02208596
Drug: Etomidate
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02128113
Drug: Vehicle Ophthalmic Solution
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opthalmic suspension manufactured to mimic RTA 408 suspension
Study: NCT02128113
Drug: Omaveloxolone Ophthalmic Suspension 0.5%
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ophthalmic suspension of RTA 408
Study: NCT02128113
Drug: Omaveloxolone Ophthalmic Suspension 1%
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% ophthalmic suspension of RTA 408
Study: NCT02524769
Drug: conjugated estrogen
Normalized name: Conjugated estrogen
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.625 mg conjugated estrogen/gram and instructions to use 0.5 grams twice weekly with the applicator.
Study: NCT01645124
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00945321
Drug: aprepitant 165 mg
Normalized name: Aprepitant 165 mg oral capsule
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of aprepitant 165 mg tablet in the fasted state during treatment period 1,2, or 3.
Study: NCT00945321
Drug: Comparator: aprepitant 185 mg
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of aprepitant 185 mg tablet in the fasted state during treatment period 1, 2, or 3.
Study: NCT00945321
Drug: Comparator: fosaprepitant 150 mg
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of fosaprepitant 150 mg intravenous infusion in the fasted state during treatment period 1,2, or 3.
Study: NCT00945321
Drug: Comparator: aprepitant with food
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of aprepitant 165 mg or 185 mg tablet in the fed state during treatment period 4.
Study: NCT02438137
Drug: Dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dimethyl fumarate capsules will be dispensed during routine study appointments. 120 mg tablets will be dispensed to facilitate dose titrations. Drug will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the medication with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
Study: NCT00111631
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: As prescribed
Study: NCT00448552
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02291913
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02291913
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-estrogen therapy
Study: NCT02291913
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-estrogen therapy
Study: NCT02291913
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anti-estrogen therapy
Study: NCT02291913
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-estrogen therapy
Study: NCT02291913
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-estrogen therapy
Study: NCT00083967
Drug: denufosol tetrasodium (INS37217) Intravitreal Injection
DrugBank: Denufosol (DB04983)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01637402
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Standard dose participants:~1,000 mg, once daily, oral administration.~Dose escalation participants:~1,000 mg, twice daily, oral administration
Study: NCT01637402
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg, twice daily, oral administration
Study: NCT00545519
Drug: thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02132949
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive 5-fluorouracil 500 mg/m\^2 IV on Day 1 of each cycle q3w.
Study: NCT02132949
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive docetaxel at a starting dose of 75 mg/m\^2 IV for the first cycle and the dose may be escalated to 100 mg/m\^2 for subsequent cycles q3w.
Study: NCT02132949
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive epirubicin 100 mg/m\^2 IV on Day 1 of each cycle q3w.
Study: NCT02132949
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive paclitaxel 80 mg/m\^2 IV given weekly.
Study: NCT02132949
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive pertuzumab at a loading dose of 840 milligrams (mg) IV loading dose, then 420 mg IV q3w.
Study: NCT02132949
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive trastuzumab at a loading dose of 8 milligrams per kilogram (mg/kg) IV, then 6 mg/kg IV q3w.
Study: NCT00351299
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine infusion titrated to effect
Study: NCT00359606
Drug: 5-Fluoro-2-Deoxycytidine (FdCyd)
Normalized name: 2'-Deoxycytidine
DrugBank: 5-fluoro-2'-deoxycytidine (DB12957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO and IV
Study: NCT00359606
Drug: Tetrahydrouridine (THU)
Normalized name: (4R)-2'-Deoxy-2',2'-difluoro-3,4,5,6-tetrahydrouridine
DrugBank: Tetrahydrouridine (DB12484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO and IV
Study: NCT00862706
Drug: Telbivudine/LDT600A
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral once daily
Study: NCT02866942
Drug: Administration of Live attenuated influenza vaccine (LAIV)
Normalized name: Chikungunya vaccine (live, attenuated)
DrugBank: Chikungunya vaccine (live, attenuated) (DB18701)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01655563
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus, a calcineurin inhibitor, is the commonest immunosuppressive agent used for maintenance immunosuppression after solid organ transplantation. The mechanism of action involves binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the generation of nuclear factor of activated T-cells, a nuclear component, resulting in inhibition of transcription of lymphokines (interleukin-2, γ-interferon). The net result is the inhibition of T-lymphocyte activation.Tacrolimus is metabolized primarily by the CYP3A enzymes in the liver particularly the CYP3A5.
Study: NCT03801148
Drug: 30 mg dexlansoprazole capsules manufactured at TOB
Normalized name: dexlansoprazole 30 MG
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole delayed-release capsules.
Study: NCT03801148
Drug: 30 mg dexlansoprazole capsules manufactured at TPC
Normalized name: dexlansoprazole 30 MG
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole delayed-release capsules.
Study: NCT03801148
Drug: 60 mg dexlansoprazole capsules manufactured at TOB
Normalized name: dexlansoprazole 60 MG
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole delayed-release capsules.
Study: NCT03801148
Drug: 60 mg dexlansoprazole capsules manufactured at TPC
Normalized name: dexlansoprazole 60 MG
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole delayed-release capsules.
Study: NCT03287713
Drug: oxygen therapy
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: conventional nasal prongs vs nasal high flow oxygen during Pulmonary Rehabilitation in Interstitial Lung Disease.
Study: NCT00047190
Drug: tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00439270
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression
Study: NCT00439270
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion, 60 or 75 mg/m\^2, administered every 3 weeks.
Study: NCT01898585
Drug: Zelboraf
Normalized name: Zelboraf
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib 960 mg twice a day until progressive disease, unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination.
Study: NCT02917512
Drug: HU007
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclosporine 0.02% + 3% trehalose
Study: NCT02917512
Drug: Restasis
Normalized name: Restasis
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 0.05%
Study: NCT02035605
Drug: ALN-AT3SC
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending doses of ALN-AT3SC by subcutaneous (sc) injection
Study: NCT02035605
Drug: Sterile Normal Saline (0.9% NaCl)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated volume to match active comparator
Study: NCT04316936
Drug: Omidria
Normalized name: Omidria
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: phenylephrine 1% and ketorolac 0.3% intraocular solution
Study: NCT03554889
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer
Study: NCT03035084
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 50,000 IU of vitamin D3
Study: NCT03035084
Drug: Vitamin D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of 50,000 IU of vitamin D2
Study: NCT00143130
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin
Study: NCT03479411
Drug: Itraconazole Powder
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole administered as a dry powder for inhalation (PUR1900)
Study: NCT03479411
Drug: Itraconazole 200 mg
Normalized name: itraconazole 200 MG
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sporanox® Oral Solution
Study: NCT02084420
Drug: Ilaprazole
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg 2 BID( 2 times / day), before breakfast and dinner
Study: NCT02084420
Drug: Pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg, BID(2 times / day), before breakfast and dinner
Study: NCT04098575
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: drug
Study: NCT03875313
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.
Study: NCT01149759
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation at 16 weeks
Study: NCT00733811
Drug: Deferiprone (DFP) and Deferoxamine (DFO)
Normalized name: Deferiprone
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sequential treatment including DFP at 75 mg/kg for four days per week and DFO by subcutaneous infusions (8-12h) at 50mg/kg/day for the remaining three days per week
Study: NCT00733811
Drug: Deferiprone (DFP)
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DFP alone at 75 mg/kg divided into three oral daily doses
Study: NCT00936182
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole daily for 30 days
Study: NCT00787969
Drug: cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Give IV
Study: NCT00787969
Drug: temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Give IV
Study: NCT01939691
Drug: Difluprednate
Normalized name: Difluprednate
DrugBank: Difluprednate (DB06781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Difluprednate 0.05% - corticosteroid eyedrop
Study: NCT01032668
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: high dose clopidogrel continuing after percutaneous coronary intervention
Study: NCT00418795
Drug: recombinant human porphobilinogen deaminase (Porphozym)
Normalized name: Porphobilinogen deaminase, human recombinant
DrugBank: Porphobilinogen deaminase, human recombinant (DB17674)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00442637
Drug: capecitabine + bevacizumab
Normalized name: Capecitabine
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ca 1250 mg/m2 daily orally continuously, B 7.5 mg/kg i.v. q 3 w
Study: NCT00366249
Drug: Ertapenem
Normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS) or enterococci coverage).
Study: NCT04383067
Drug: Proleukin
Normalized name: Proleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: high-dose (720,000 IU/kg) IL-2 will be administered every 8 hours, to tolerance. A maximum of 10 doses will be administered
Study: NCT01825850
Drug: Gemigliptin
Normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01825850
Drug: Irbesartan
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00754065
Drug: Ortho Tri Cyclen Lo
Normalized name: ORTHO TRI CYCLEN Lo KIT
DrugBank: Norgestimate (DB00957)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose--Ethinylestradiol (EE) + Norgestimate (NGM) Triphasic 21-day regimen. Daily oral administration of one encapsulated Ortho Tri-Cyclen Lo for 28 days per Cycle, for 13 treatment cycles: Days 1-7, 0.025 mg EE+0.180 NGM; Days 8-14, 0.025 mg EE+0.215 NGM; Days 15-21, 0.025 mg EE+0.250 NGM; Days 27-28, placebo
Study: NCT03106922
Drug: Klean-prep
Normalized name: Noxzema Clean
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Powder for oral solution:~macrogol 3350 59.000 g, anhydrous sodium sulphate 5.685 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g, potassium chloride 0.7425 g.~One sachet to be dissolved in 1 L of water
Study: NCT01238146
Drug: bendamustine hydrochloride
Normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01238146
Drug: obatoclax mesylate
Normalized name: mesylate
DrugBank: Obatoclax (DB12191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00504023
Drug: imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The patient will be seen in clinic every six weeks during treatment for examination. Imiquimod cream is to be applied 3 times per week for 12 weeks.
Study: NCT02639637
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will receive sitagliptin 100 mg daily for 7 days prior to one of the study days.
Study: NCT02639637
Drug: Neuropeptide Y
Normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the study days, neuropeptide Y will be infused through an intra-arterial line. There will be four doses of neuropeptide Y used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
Study: NCT02639637
Drug: Enalaprilat
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ninety minutes after the last dose of neuropeptide Y, enalaprilat will be infused through the intra-arterial line at 0.33 µg/min/100mL of forearm volume. After 30 minutes, a second infusion of neuropeptide Y will begin. Similar to the previous neuropeptide infusion, four doses of neuropeptide Y will be used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
Study: NCT02639637
Drug: Valsartan 160mg
Normalized name: VALSARTAN 160MG CAP
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan 160 mg/d for 7 days prior to one of the study days.
Study: NCT00110552
Drug: Salvia officinalis (sage)
Normalized name: Salvia officinalis (sage) oil
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dosage
Study: NCT01053325
Drug: Cotrimoxazole prophylaxis
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily prophylaxis with cotrimoxazole
Study: NCT04115423
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A humanized monoclonal antibody against the interleukin-6 receptor, which is mainly for the treatment of rheumatoid arthritis.
Study: NCT00753493
Drug: intravenous topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single 25 mg IV dose given in addition to subject's normal morning dose of topiramate
Study: NCT00204685
Drug: dornase alfa
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01158417
Drug: Resveratrol 40 mg oral three times a day
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug
Study: NCT01158417
Drug: Resveratrol 500 mg oral once daily.
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 500 mg oral once daily.
Study: NCT00557596
Drug: AEG35156
Normalized name: AEG35156
DrugBank: AEG35156 (DB06184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AEG35156 will be given as a 2-hour intravenous infusion once weekly, only on weeks when gemcitabine is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1
Study: NCT00683800
Drug: desvenlafaxine succinate (DVS) SR
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titration with 50 mg tablets once daily for 7 days, then 100mg tablets once daily from day 8 to day 365, then taper with 50 mg tablets once daily for 7 days, followed by 25 mg tablets once daily for 7 days.
Study: NCT02362139
Drug: The study group
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation\<4cm).
Study: NCT02247375
Drug: Low dose of BIIL 284 BS tablets
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03305445
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab (1mg/kg)
Study: NCT03305445
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (3mg/kg)
Study: NCT01798667
Drug: DA-8031
Normalized name: DA-8031
DrugBank: DA-8031 (DB19024)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02546531
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00623194
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treat-to-target dose titration scheme (individually adjusted), injection s.c. (under the skin), once or twice daily.
Study: NCT00623194
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treat-to target dose titration scheme (individually adjusted), injection s.c. (under the skin), at larger meals.